Nautilus Biotechnology, Inc. (NAUT) shareholders
Close on Nov 17, 2026Market cap $300.60MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Parag Mallick | 22,557,411 | 17.60% | 13D (active) amendment | Mar 2, 2026 |
| Sujal Patel | 21,249,965 | 16.30% | 13D (active) amendment | Mar 2, 2026 |
| Benjamin A. Horowitz Joint filing with Marc L. Andreessen (6.00%), AH Bio Fund II, L.P. (5.60%) and 1 more | 7,684,932 | 6.00% | 13D (active) amendment | Aug 26, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NAUT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Perceptive Advisors LLC | 11,634,211 | 9.13% | $21.76M | −960,000 | 0.33% |
| a16z Capital Management, L.L.C. | 9,063,054 | 7.12% | $16.95M | −8,590,863 | 0.12% |
| Cercano Management LLC | 7,172,985 | 5.63% | $13.41M | – | 1.79% |
| BlackRock, Inc. | 2,687,226 | 2.11% | $5.03M | +2,499,555 | 0.00% |
| Vanguard Capital Management LLC | 2,549,979 | 2.00% | $4.77M | +4,382 | 0.00% |
| Comprehensive Financial Management LLC | 2,207,619 | 1.73% | $4.13M | – | 0.14% |
| Citadel Advisors LLC | 1,896,192 | 1.49% | $3.55M | New | 0.00% |
| Geode Capital Management, LLC | 1,265,535 | 0.99% | $2.37M | +662,011 | 0.00% |
| Acadian Asset Management LLC | 1,055,461 | 0.83% | $1.97M | +314,215 | 0.00% |
| Clearstead Advisors, LLC | 892,787 | 0.70% | $1.67M | −1,436,997 | 0.02% |
| Susquehanna International Group, Llp | 890,949 | 0.70% | $1.67M | New | 0.00% |
| Sentinel Trust Co Lba | 750,000 | 0.59% | $1.40M | – | 0.12% |
| Barclays PLC | 725,321 | 0.57% | $1.36M | +651,996 | 0.00% |
| Renaissance Technologies LLC | 690,514 | 0.54% | $1.29M | +424,814 | 0.00% |
| JPMorgan Chase & Co | 614,177 | 0.48% | $1.10M | New | 0.00% |
| State Street Corp | 559,508 | 0.44% | $1.05M | +343,238 | 0.00% |
| Dimensional Fund Advisors LP | 475,844 | 0.37% | $889.25K | +146,721 | 0.00% |
| Northern Trust Corp | 381,234 | 0.30% | $712.91K | +274,223 | 0.00% |
| Hrt Financial LP | 361,073 | 0.28% | $675.00K | +295,819 | 0.00% |
| Vanguard Fiduciary Trust Co | 353,093 | 0.28% | $660.28K | +47,567 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 93 | 50M | 39.4% | 30 / 29 | 12 / 17 | 11M | 15M |
| Q1 2026 | 81 | 54M | 42.7% | 25 / 16 | 17 / 9 | 7M | 1M |
| Q4 2025 | 68 | 58M | 45.9% | 11 / 19 | 14 / 7 | 2M | 2M |
| Q3 2025 | 68 | 58M | 45.5% | 9 / 9 | 28 / 12 | 1M | 3M |
| Q2 2025 | 71 | 60M | 46.9% | 12 / 25 | 17 / 28 | 4M | 7M |
| Q1 2025 | 88 | 63M | 49.3% | 14 / 19 | 30 / 12 | 1M | 2M |
| Q4 2024 | 88 | 64M | 50.1% | 16 / 26 | 17 / 11 | 1M | 1M |
| Q3 2024 | 83 | 64M | 50.4% | 9 / 23 | 12 / 2 | 4M | 0M |
| Q2 2024 | 77 | 64M | 50.3% | 8 / 23 | 20 / 4 | 1M | 1M |
| Q1 2024 | 73 | 64M | 50.3% | 5 / 18 | 24 / 8 | 1M | 1M |
| Q4 2023 | 76 | 64M | 50.2% | 8 / 26 | 22 / 6 | 22M | 2M |
| Q3 2023 | 75 | 45M | 35.4% | 5 / 25 | 12 / 5 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
58 funds held NAUT in Q2 2026, 71% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of NAUT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,930,610 | 1.52% | $3.61M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,072,858 | 0.84% | $2.01M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 543,262 | 0.43% | $1.02M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 541,671 | 0.43% | $529.21K | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 387,428 | 0.30% | $724.49K | 0.00% | Jun 30, 2026 |
| JPMorgan Small Cap Value Fund | 332,886 | 0.26% | $622.50K | 0.05% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 250,996 | 0.20% | $687.73K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 166,544 | 0.13% | $311.44K | 0.02% | Jun 30, 2026 |
| Ultra-Small Company Market Fund | 130,000 | 0.10% | $243.10K | 0.16% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 121,119 | 0.10% | $118.33K | 0.00% | Jul 31, 2026 |
| U.S. Small Cap Portfolio | 108,163 | 0.08% | $105.68K | 0.00% | Jul 31, 2026 |
| U.S. Small Cap Equity Fund | 100,386 | 0.08% | $98.08K | 0.01% | Jul 31, 2026 |
| Master Small Cap Index Series | 92,957 | 0.07% | $173.83K | 0.00% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 91,529 | 0.07% | $250.79K | 0.00% | May 31, 2026 |
| Dimensional U.S. Small Cap ETF | 84,337 | 0.07% | $82.40K | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Sujal M. Patel | CEO, President, and Secretary, Director, 10% owner | 17,461,232 | 13.71% | Mar 4, 2026 |
| Parag Mallick | Chief Scientist, Director, 10% owner | 20,493,392 | 16.09% | Mar 4, 2026 |
| Subramanian Sankar | Senior VP, Product Development | 91,250 | 0.07% | Mar 4, 2026 |
| Gwen E. Weld | Chief People Officer | 30,000 | 0.02% | Mar 4, 2026 |
| Kentaro Suzuki | Chief Marketing Officer | 4,000 | 0.00% | Mar 4, 2026 |
| Anna Mowry | CFO and Treasurer | 83,000 | 0.07% | Mar 4, 2026 |
| Matthew B. Murphy | General Counsel | 75,390 | 0.06% | Mar 4, 2026 |
| Nicholas A. Nelson | CBO & Senior VP, Bus. Dev. | – | – | Mar 4, 2025 |
| Matthew S. McIlwain | Director | 6,479,845 | 5.09% | Jun 22, 2026 |
| Karen Akinsanya | Director | – | – | Jun 22, 2026 |
| Farzad Nazem | Director | 1,888,146 | 1.48% | Jun 22, 2026 |
| Epperly Melissa B, | Director | – | – | Jun 22, 2026 |
| Matthew L. Posard | Director | 140,000 | 0.11% | Jun 22, 2026 |
| Andreessen Horowitz LSV Fund II, L.P. | 10% owner | – | – | Jun 4, 2026 |
| AH Bio Fund II, L.P. | 10% owner | 12,653,917 | 9.93% | Jun 4, 2026 |
| Marc L. Andreessen | 10% owner | – | – | Jun 4, 2026 |
| Benjamin A. Horowitz | 10% owner | – | – | Jun 4, 2026 |
| AH Equity Partners LSV II, L.L.C. | 10% owner | – | – | Jun 4, 2026 |
| AH Equity Partners Bio II, L.L.C. | 10% owner | 17,653,917 | 13.86% | Jun 4, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| AH Bio Fund II, L.P. 10% owner | Jun 2, 2026 | Sale | −384,026 | $2.35 | $902.46K | 971,885 |
| AH Bio Fund II, L.P. 10% owner | Jun 2, 2026 | Sale | −4,615,974 | $2.35 | $10.85M | 11,682,032 |
| Sujal M. Patel CEO, President, and Secretary, Director, 10% owner | Mar 4, 2026 | Buy | +25,000 | $2.61 | $65.25K | 10,366,721 |
| Kentaro Suzuki Chief Marketing Officer | Nov 6, 2025 | Buy | +4,000 | $1.49 | $5.96K | 4,000 |
| Sujal M. Patel CEO, President, and Secretary, Director, 10% owner | Sep 8, 2025 | Buy | +83,500 | $0.68 | $56.78K | 10,341,721 |
| Sujal M. Patel CEO, President, and Secretary, Director, 10% owner | Sep 5, 2025 | Buy | +116,500 | $0.67 | $78.06K | 10,258,221 |
| Matthew B. Murphy General Counsel | Sep 4, 2025 | Buy | +20,000 | $0.64 | $12.80K | 74,140 |
| Anna Mowry CFO and Treasurer | May 29, 2025 | Buy | +15,000 | $0.77 | $11.55K | 83,000 |
| Parag Mallick Chief Scientist, Director, 10% owner | May 12, 2025 | Buy | +1,500 | $0.73 | $1.10K | 20,493,392 |
| Parag Mallick Chief Scientist, Director, 10% owner | May 8, 2025 | Buy | +12,000 | $0.73 | $8.76K | 20,491,892 |
| Sujal M. Patel CEO, President, and Secretary, Director, 10% owner | Mar 20, 2025 | Buy | +23,933 | $1.00 | $23.93K | 10,141,721 |
| Sujal M. Patel CEO, President, and Secretary, Director, 10% owner | Mar 19, 2025 | Buy | +53,300 | $0.99 | $52.77K | 10,117,788 |
| Mary E. Godwin Senior VP, Operations | Sep 23, 2024 | Sale | −47,031 | $2.87 | $134.98K | 0 |
| Mary E. Godwin Senior VP, Operations | Sep 23, 2024 | Option exercise | +47,031 | $0.46 | $21.63K | 47,031 |
| Mary E. Godwin Senior VP, Operations | Sep 17, 2024 | Option exercise | +35,000 | $0.46 | $16.10K | 35,000 |
| Mary E. Godwin Senior VP, Operations | Sep 17, 2024 | Sale | −35,000 | $2.85 | $99.75K | 0 |
| Sujal M. Patel CEO, President, and Secretary, Director, 10% owner | Mar 11, 2024 | Buy | +12,044 | $2.84 | $34.20K | 10,064,488 |
| Sujal M. Patel CEO, President, and Secretary, Director, 10% owner | Mar 8, 2024 | Buy | +2,430 | $2.99 | $7.27K | 10,052,444 |
| Sujal M. Patel CEO, President, and Secretary, Director, 10% owner | Mar 7, 2024 | Buy | +18,854 | $2.89 | $54.49K | 10,050,014 |
| Sujal M. Patel CEO, President, and Secretary, Director, 10% owner | Mar 6, 2024 | Buy | +9,267 | $2.70 | $25.02K | 10,031,160 |
| Sujal M. Patel CEO, President, and Secretary, Director, 10% owner | Mar 5, 2024 | Buy | +7,405 | $2.65 | $19.62K | 10,021,893 |
| Subramanian Sankar Senior VP, Product Development | Sep 27, 2022 | Buy | +5,000 | $2.03 | $10.15K | 91,250 |
| Subramanian Sankar Senior VP, Product Development | Sep 26, 2022 | Buy | +10,000 | $2.03 | $20.30K | 86,250 |
| Gwen E. Weld Chief People Officer | Sep 23, 2022 | Buy | +30,000 | $2.03 | $60.90K | 30,000 |
| Subramanian Sankar Senior VP, Product Development | Sep 16, 2022 | Buy | +35,000 | $2.16 | $75.60K | 75,000 |
| Subramanian Sankar Senior VP, Product Development | Sep 15, 2022 | Buy | +40,000 | $2.19 | $87.60K | 40,000 |
| Anna Mowry CFO and Treasurer | Aug 19, 2022 | Buy | +17,500 | $2.30 | $40.25K | 56,750 |
| Matthew B. Murphy General Counsel | Aug 15, 2022 | Buy | +7,500 | $2.84 | $21.30K | 54,140 |
| Matthew B. Murphy General Counsel | Aug 12, 2022 | Buy | +2,500 | $2.85 | $7.13K | 46,640 |
| Sujal M. Patel CEO, President, and Secretary, Director, 10% owner | Aug 8, 2022 | Buy | +8,346 | $2.93 | $24.45K | 10,014,488 |
| Sujal M. Patel CEO, President, and Secretary, Director, 10% owner | Aug 5, 2022 | Buy | +41,654 | $2.92 | $121.63K | 10,006,142 |
| Anna Mowry CFO and Treasurer | Jun 27, 2022 | Buy | +5,500 | $2.75 | $15.13K | 39,250 |
| Matthew B. Murphy General Counsel | May 12, 2022 | Award | +10,000 | $3.28 | $32.80K | 44,140 |
| Sujal M. Patel CEO, President, and Secretary, Director, 10% owner | May 9, 2022 | Buy | +50,000 | $3.96 | $198.00K | 9,964,488 |
| Sujal M. Patel CEO, President, and Secretary, Director, 10% owner | Mar 4, 2022 | Option exercise | +100 | $10.00 | $1.00K | 9,914,488 |
| Sujal M. Patel CEO, President, and Secretary, Director, 10% owner | Mar 3, 2022 | Buy | +50,000 | $3.60 | $180.00K | 9,914,388 |
| Parag Mallick Chief Scientist, Director, 10% owner | Dec 21, 2021 | Gift | −210,000 | – | – | 20,479,892 |
| Life Sciences Master Fund Ltd Perceptive 10% owner | Dec 8, 2021 | Buy | +200,000 | $5.36 | $1.07M | 9,111,151 |
| Sujal M. Patel CEO, President, and Secretary, Director, 10% owner | Dec 1, 2021 | Buy | +88,022 | $4.73 | $416.34K | 9,864,388 |
| Matthew L. Posard Director | Dec 1, 2021 | Buy | +10,000 | $4.46 | $44.60K | 40,000 |
| Matthew L. Posard Director | Dec 1, 2021 | Buy | +10,000 | $4.45 | $44.50K | 50,000 |
| Matthew L. Posard Director | Dec 1, 2021 | Buy | +10,000 | $4.50 | $45.00K | 30,000 |
| Sujal M. Patel CEO, President, and Secretary, Director, 10% owner | Nov 30, 2021 | Buy | +161,978 | $4.72 | $764.54K | 9,776,366 |
| Matthew L. Posard Director | Nov 30, 2021 | Buy | +20,000 | $4.57 | $91.40K | 20,000 |
| Anna Mowry CFO and Treasurer | Nov 24, 2021 | Buy | +15,000 | $4.58 | $68.70K | 32,500 |
| Matthew S. McIlwain Director | Nov 15, 2021 | Buy | +100,000 | $5.30 | $530.00K | 459,075 |
| Matthew S. McIlwain Director | Aug 26, 2021 | Buy | +11,709 | $7.71 | $90.28K | 359,075 |
| Matthew S. McIlwain Director | Aug 25, 2021 | Buy | +11,693 | $7.74 | $90.50K | 347,366 |
| Matthew S. McIlwain Director | Aug 24, 2021 | Buy | +13,568 | $7.68 | $104.20K | 335,673 |
| Matthew B. Murphy General Counsel | Aug 13, 2021 | Buy | +5,000 | $7.56 | $37.80K | 34,140 |
| Anna Mowry CFO and Treasurer | Aug 12, 2021 | Buy | +17,500 | $7.71 | $134.93K | 17,500 |
| Life Sciences Master Fund Ltd Perceptive – | Jun 9, 2021 | Buy | +5,500,000 | $10.00 | $55.00M | 5,997,038 |
| Life Sciences Master Fund Ltd Perceptive – | Jun 9, 2021 | Other | +2,914,113 | – | – | 8,911,151 |
| Michael Seth Altman Director | Jun 9, 2021 | Conversion | +499,000 | – | – | 499,000 |
| Michael Seth Altman Director | Jun 9, 2021 | Conversion | +3,647,500 | – | – | 3,647,500 |
| Michael Seth Altman Director | Jun 9, 2021 | Conversion | −499,000 | – | – | 0 |
| Advisors Llc Perceptive Director | Jun 3, 2021 | Buy | +330,050 | $10.05 | $3.32M | 489,975 |
| Life Sciences Master Fund Ltd Perceptive – | May 24, 2021 | Buy | +7,063 | $10.05 | $70.98K | 497,038 |
| Life Sciences Master Fund Ltd Perceptive Director | May 20, 2021 | Buy | +159,925 | $10.05 | $1.61M | 159,925 |
| Sciences Holdings ARYA III 10% owner | Aug 11, 2020 | Other | +499,000 | $10.00 | $4.99M | 499,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Nautilus Biotechnology's stock actually held short. Settlement fails (shares not delivered on time) peaked at 382,909 shares on Oct 6, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Mary E. Godwin Officer | Dec 17, 2024 | 38,337 | $74.26K | Dec 17, 2024 | Stock Option Exercise |
| Mary E. Godwin Officer | Dec 9, 2024 | 35,000 | $74.59K | Dec 9, 2024 | Stock Option Exercise |
| Mary E. Godwin Officer | Dec 3, 2024 | 60,000 | $131.78K | Dec 3, 2024 | Stock Option Exercise |
| Mary E. Godwin Officer | Nov 26, 2024 | 60,000 | $136.51K | Nov 26, 2024 | Stock Option Exercise |
| Mary E. Godwin Officer | Nov 21, 2024 | 30,000 | $70.62K | Nov 21, 2024 | Stock Option Exercise |
| Mary E. Godwin Officer | Nov 19, 2024 | 30,000 | $68.05K | Nov 19, 2024 | Stock Option Exercise |
| Mary E. Godwin Officer | Nov 12, 2024 | 40,000 | $98.88K | Nov 11, 2024 | Stock Option Exercise |
| Mary E. Godwin Officer | Nov 8, 2024 | 31,078 | $78.16K | Nov 8, 2024 | Stock Option Exercise |
| Mary E. Godwin Officer | Nov 7, 2024 | 28,922 | $79.64K | Nov 7, 2024 | Stock Option Exercise |
| Mary E. Godwin Officer | Sep 23, 2024 | 47,031 | $134.74K | Sep 23, 2024 | Stock Option Exercise |
| Mary E. Godwin Officer | Sep 17, 2024 | 35,000 | $99.87K | Sep 17, 2024 | Stock Option Exercise |
See a number that looks wrong?